iLTB - international Leukemia/Lymphoma Target Board
--- Information for health care providers ---
The international Leukemia/Lymphoma Target Board (iLTB) is a virtual discussion platform designed to assist physicians in choosing the optimal and available treatment for their patients diagnosed with relapsed or refractory leukemia or lymphoma without standard-of-care treatment.
The iLTB started in early 2023 and has already discussed 112 cases from 25 different countries encompassing a wide spectrum of malignant hematological diseases in various disease stages.
%2520%257B%2520%255Bnative%2520code%255D%2520%257D&w=1080&q=100)
Panel of European experts
Panel of European experts
The iLTB conducts weekly virtual meetings via Microsoft MS Teams wherein 1-3 cases are being discussed. During the meeting, the treating physician presents his patient to a panel of European experts specializing in leukemia and lymphoma, comprising specific expertise for early clinical trials, molecular biology, diagnostics, and immunology.
Preceding the iLTB meeting, the iLTB team collaborates with the treating physician to formulate the patient presentation, ensuring the inclusion of all available recent diagnostic data and validation of all potential actionable events.
After the meeting, the iLTB team summarizes the discussion into a formal letter including the patient presentation, the discussed diagnostic findings, and the panel recommendation.
Clinical study
Clinical study
The iLTB is a non-interventional clinical study (NCT05270096) in the context of the Innovative Therapies for Children with Cancer consortium (ITCC 107). The sponsor team at the Princess Máxima Center works with National Coordinating Centers to establish clinical trial contracts. While we are working to get the contracts in place, the iLTB accepts pilot cases for discussion.
How do I present a patient for discussion?
How do I present a patient for discussion?
Physicians interested in having their patient discussed in the iLTB are requested to follow these steps:
If the iLTB is open in your country, please get in touch with your National Coordinator for registration of the case in the iLTB registry. (NCC list)
For discussion of a pilot case, don't hesitate to get in touch with the iLTB team at iLTB@prinsesmaximacentrum.nl.
A template presentation with all the information needed for the discussion to present the patient most efficiently is available and will be sent by the iLTB coordinator if required.
Please contact the iLTB coordinating team via email if you need assistance in collecting molecular information by performing NGS on your patient (RNA seq or WES).
Any inquiries are welcomed and will be promptly addressed.
Last updated: August 2025
Published results: Identifying and prioritizing new options
The International Leukemia/Lymphoma Target Board is a virtual consultation platform in which experts from several countries in the fields of blood cancer, genetics, stem cell transplantation, immunotherapy and clinical studies jointly formulate recommendations. An average of 28 experts were involved per meeting.
The evaluation of the first year of the iLTB has been published in Haematologica. Dr. Judith Boer and Uri Ilan coordinated the iLTB under the leadership of research group leaders Prof. Dr. Monique den Boer and Prof. Dr. Michel Zwaan.
Therapeutic strategy
Pediatric oncologists could submit cases directly to the iLTB. In the first year, 42 children were discussed. For 41 of them, a concrete treatment recommendation could be formulated. In four out of five cases, this recommendation was subsequently applied.
Thanks to the iLTB, more than one in three (36%) of these children were able to participate in a clinical trial or a so-called ‘named patient protocol’, in which an as-yet experimental medicine is made available. That is three times as much as before. This often took place via international referrals, because certain treatments were not available in the child’s own country.
The results show that an international team of experts genuinely helps in identifying and prioritizing new options for children with a very difficult-to-treat form of blood cancer. In nearly 40% of patients, the recommendation even led to a completely new therapeutic strategy.
In its first year, the iLTB platform therefore achieved its most important goal: increasing access to innovative and experimental treatments for high‑risk children. The consultation will be continued in the coming years. The discussed children will be followed for two years to enable assessment of the clinical added value of the recommended treatments.
Not a health care provider?
Please look here for more information on the iLTB